Result of AGM

RNS Number : 2617T

Evgen Pharma PLC

16 July 2020

 

Evgen Pharma plc

  ("Evgen Pharma" or the "Company")

Result of AGM

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that at the AGM held earlier today, all resolutions were duly passed.

A copy of the presentation will be available on the Company's website later today.

Enquiries:

Evgen Pharma plc www.evgen.com		via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com		[phone]
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR	[phone] or [e-mail]
Paul McManus / Anna Dunphy		[phone] / [phone]

About Evgen Pharma plc  

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases . The Company's core technology is Sulforadex ®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.   

For further information, please visit:  www.evgen.com  

 

END

 

 

RAGEADXKFSEEEFA